Hoofddorp, the Netherlands, 14 July 2019. IGEA Pharma N.V. (the “Company” and together with its subsidiaries “IGEA” or the “Group”) today announced the launch of Alz1, the first solution designed to detect and reduce high free copper levels in the bloodstream – a risk factor associated with Alzheimer’s disease – through a first-of-its-kind in-home blood test and a dietary supplement for those with elevated free copper levels.

Continue reading →


Minutes of the first annual general meeting of IGEA Pharma N.V., a public limited liability company (naamloze vennootschap) incorporated under the laws of the Netherlands, having its corporate seat at Hoofddorp, the Netherlands (the “Company”), held on 6 June 2019 at 10:00 am CET at Hoofddorp Transpolis, Polarisavenue 1, 2123 JH Hoofddorp, the Netherlands (the “Meeting”).

Continue reading →




Dear Shareholder,

On behalf of IGEA Pharma N.V. (the “Company”), it is a pleasure to invite you to attend the Annual General Meeting on 6 June 2019 (the “AGM”). The meeting will be held at Hoofddorp Transpolis, Polarisavenue 1, 2123 JH Hoofddorp, the Netherlands. The meeting will start at 10.00 am. CET.

Continue reading →


Hoofddorp, the Netherlands, 28 March 2019. IGEA Pharma N.V. (SIX: IGPH) today announced an update of its corporate calendar. The annual general meeting is newly set-up for 27 May 2019. The presentation of the 2018 financials and the Q1 2019 financials is newly set-up for 26 April 2019 and 27 May 2019 respectively. The update is due to some additional work necessary to harmonize with SIX and Dutch disclosure requirements. The updated corporate calendar is available under igeapharma.nl/investors-relations/

Continue reading →